Alterity Therapeutics Limited (ATHE): Price and Financial Metrics


Alterity Therapeutics Limited (ATHE): $0.68

0.01 (+1.05%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ATHE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ATHE Stock Price Chart Interactive Chart >

Price chart for ATHE

ATHE Price/Volume Stats

Current price $0.68 52-week high $2.75
Prev. close $0.67 52-week low $0.58
Day low $0.67 Volume 22,000
Day high $0.68 Avg. volume 1,469,901
50-day MA $0.75 Dividend yield N/A
200-day MA $0.98 Market Cap 15.30M

Alterity Therapeutics Limited (ATHE) Company Bio


Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.


ATHE Latest News Stream


Event/Time News Detail
Loading, please wait...

ATHE Latest Social Stream


Loading social stream, please wait...

View Full ATHE Social Stream

Latest ATHE News From Around the Web

Below are the latest news stories about Alterity Therapeutics Ltd that investors may wish to consider to help them evaluate ATHE as an investment opportunity.

Alterity announces publication of animal study on lead asset

Alterity Therapeutics (ATHE) has added ~10% in the pre-market after announcing that the Journal of Parkinson''s Disease published data from an animal study, which was designed to

Seeking Alpha | January 28, 2022

Alterity Therapeutics Highlights New Publications On ATH434 In Parkinson's Disease

Alterity Therapeutics's (NASDAQ: ATHE) data in an animal model of Multiple System Atrophy (MSA) were published in the Journal of Parkinson's Disease. The publication describes a study evaluating the efficacy of ATH434 in genetically altered mice that develop manifestations of MSA. The investigation demonstrated that ATH434 treatment reduced both the toxic oligomeric and aggregated forms of α–synuclein, a central nervous system protein essential for the normal function of nerve cells. At the same

Yahoo | January 28, 2022

Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data in an animal model of Multiple System Atrophy (MSA) were published in the Journal of Parkinson's Disease. MSA is a devastating neurodegenerative disorder without approved therapy.

Yahoo | January 28, 2022

Appendix 4C - Q2 FY22 Quarterly Cash Flow Report

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31st December 2021 (Q2 FY22).

Yahoo | January 27, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's the final day of trading this week and we're starting it off with an overview of the biggest pre-market stock movers for Friday!

William White on InvestorPlace | January 7, 2022

Read More 'ATHE' Stories Here

ATHE Price Returns

1-mo -5.56%
3-mo -16.85%
6-mo -33.33%
1-year -49.25%
3-year -48.97%
5-year -67.77%
YTD -5.56%
2021 -46.27%
2020 71.79%
2019 -39.06%
2018 -58.97%
2017 91.41%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7022 seconds.